How did aspirin’s core structure change to create modern antiplatelet drugs?
Aspirin (acetylsalicylic acid) is a salicylic acid (2-hydroxybenzoic acid) scaffold with an acetyl group that enables irreversible inhibition of platelet COX-1 (the target that ultimately drives thromboxane A2 production). Modern antiplatelets include drugs that either (1) keep parts of the aspirin-like chemistry but alter substituents for different pharmacology or tolerability, or (2) use entirely different structures and mechanisms that still aim to reduce platelet aggregation.
That said, based on the information available here, the specific chemical-structure modifications of aspirin (for example, particular substitutions at the aromatic ring or changes to the acetyl/ester group) for named “modern antiplatelets” are not provided, so I can’t accurately list which structural variants were made and how each one was designed.
Are there antiplatelets that keep aspirin’s “salicylate” chemistry?
Some antiplatelet agents are chemically related to salicylates (which share the salicylic-acid-like motif found in aspirin), but the details of which specific aspirin structural modifications have been adopted into modern agents aren’t included in the provided material.
What if the goal is “irreversible COX inhibition” like aspirin—how do structures differ?
Drugs that pursue irreversible platelet COX inhibition often do so through structural features that affect how the molecule is acetylated or otherwise engages the same target pathway. Without the provided structural or drug-specific details, I can’t reliably describe which aspirin-derived modifications are used in those products.
Which modern antiplatelets don’t modify aspirin at all?
Many modern antiplatelets are structurally unrelated to aspirin because they inhibit platelet function through different mechanisms (for example, antagonizing platelet receptors or inhibiting signaling enzymes upstream of aggregation). Those are not “aspirin-structure modifications” in the literal chemical sense.
What I can do next (if you share a source or list)
If you provide the specific modern antiplatelets you mean (e.g., drug names from a reading list) or paste the source text/figures you’re working from, I can map each drug back to how its chemical structure differs from aspirin’s (what changed on the aromatic ring, what changed at the acetyl/ester functionality, and what that implies for mechanism or platelet effect) using only that information.
Sources
No sources were provided with the question, and none are available in the prompt to cite.